AZAMIAN BOBAK R. (President and CEO) sold 50.9% of their position (34.60K shares) of TARSUS PHARMACEUTICALS, INC. on the open market
Open‑market sale worth $2.36M — a major position exit. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 3 sales
Filed: 3/19/2026ACC: 0001827672-26-000007
DirectorOfficer10% Owner· President and CEO
Since Oct 2020
-34.60K
Net shares
Net seller
$2.36M
Total sold
3
Open market trades
0B · 3S
3
Total transactions
34.60K disposed
Non-Derivative Transactions3
Common Stock
Direct
Shares
−10.97K
Price / share
$69.42
Trade value
$761.68K
% of position
16.1%
3/17/2026
68.02K→57.05K
Common Stock
Direct
Shares
−11.67K
Price / share
$68.71
Trade value
$801.64K
% of position
20.4%
3/18/2026
57.05K→45.38K
Common Stock
Direct
Shares
−11.96K
Price / share
$67.00
Trade value
$801.59K
% of position
26.4%
3/19/2026
45.38K→33.42K
Total
Net shares
−34.60K
Net value
-$2.36M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 3/17/2026 | S · Sale | −10.97K | $69.42 | $761.68K | 16.1% | 68.02K | 57.05K |
| Common Stock Direct | 3/18/2026 | S · Sale | −11.67K | $68.71 | $801.64K | 20.4% | 57.05K | 45.38K |
| Common Stock Direct | 3/19/2026 | S · Sale | −11.96K | $67.00 | $801.59K | 26.4% | 45.38K | 33.42K |
| Total | −34.60K | -$2.36M | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)1
Common Stock
IndirectShares owned857.99K
Total
857.99K indirect857.99K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 857.99K | Indirect |
| Total | 857.99K | 857.99K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported